Hepatic iron overload, a possible consequence of treatment with imatinib mesylate: A case report

Cases Journal

Volumn 2, Issue 5, 2009, Pages

  Maiti, Baidehi ^a   Setrakian, Sebouh ^a   Daw, Hamed A ^b  

^a FAIRVIEW HOSPITAL   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; FERRITIN; HEMOGLOBIN; IMATINIB;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FATIGUE; FERRITIN BLOOD LEVEL; FEVER; HUMAN; LEUKOCYTE COUNT; LEUKOCYTOSIS; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER HEMOSIDEROSIS; MALE; NEUTROPHIL COUNT; NUCLEAR MAGNETIC RESONANCE IMAGING; PHILADELPHIA 1 CHROMOSOME; PHLEBOTOMY; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; SPLENOMEGALY; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 77953372580     PISSN: 17571626     EISSN: None     Source Type: Journal    
DOI: 10.1186/1757-1626-2-7526     Document Type: Article

References (15)

1. Soverini S, Martinelli G, Iacobucci I, Baccarani M: Imatinib mesylate for the treatment of chronic myeloid leukemia. Expert Rev Anticancer Ther 2008, 8(6):853-864. Review.
2. Schwetz B: New treatment for chronic myeloid leukemia. JAMA 2001, 286(1):35.
3. Rodriguez-Frias EA, Lee WM: Cancer chemotherapy I: hepatocellular injury. Clin Liver dis 2007, 11:641-662.
4. Al Sobhi E, Zahrani Z, Zevallos E, Zuraiki A: Imatinib-induced immune hepatitis: case report and literature review. Hematology 2007, 12(1):49-53.
5. Deininger Michael WN, O'Brien Stephen G, Ford John M, Druker Brian J: Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003, 21:4255-4256.
6. Belasco KT, Miller RA: Intradermal tissue hemosiderosis presenting as slate-gray hyperpigmentation during treatment with imatinib mesylate. J Am Acad Dermatol 2007, 56(2):AB171.
7. Kong JH: Early Imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukemia. Acta Haematol 2007, 118(4):205-208.
8. Hochhaus A: First-Line management of CML: a state of the art review. J Natl Compr Canc Netw 2008, 6(Suppl 2):S1-S10.
9. Goldman JM, Melo JV: BCR-ABL in chronic myelogenous leukemia - how does it work? Acta Haematol 2008, 119(4):212-217.
10. Walid S, Ayoub WS, Geller SA, Tran T, Martin P, Vierling JM, Poordad FF: Imatinib (Gleevec)-induced hepatotoxicity. J ClinGastroentero 2005, 39(1):75-77.
11. James C, Trouette H, Marit G, Cony-Makhoul P, Mahon FX: Histological features of acute hepatitis after imatinib mesylatetreatment. Leukemia 2003, 17(5):978-979.
12. Kikuchi S, Muroi K, Takahashi S, Kawano-Yamamoto C, Takatoku M, Miyazato A, Nagai T, Mori M, Komatsu N, Ozawa K: Severe hepatitis and complete molecular response caused by imatinib mesylate: Possible association of its serum concentration with clinical outcomes. Leuk Lymphoma 2004, 45(11):2349-2351.
13. Ikeda K, Shiga Y, Takahashi A, Kai T, Kimura H, Takeyama K, Noji H, Ogawa K, Nakamura A, Ohira H, Sato Y, Maruyama Y: Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma 2006, 47(1):155-157.
14. Ohyashiki K, Kuriyama Y, Nakajima A, Tauchi T, Ito Y, Miyazawa H, Kimura Y, Serizawa H, Ebihara Y: Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia 2002, 16(10):2160-2161.
15. Ferrero D, Pogliani EM, Rege-Cambrin G, Fava C, Mattioli G, Dellacasa C, Campa E, Perfetti P, Fumagalli M, Boccadoro M: Corticosteroids can reverse severe imatinib-induced hepatotoxicity. Haematologica 2006, 91(Suppl 6):ECR27.